Atomoxetine restores the response inhibition network in Parkinson’s disease

Impairments in response inhibition in Parkinson’s disease may reflect loss of noradrenaline and impaired fronto-subcortical connectivity. Rae et al. show that the noradrenaline reuptake inhibitor atomoxetine can restore functional connectivity in the inhibition network. Individual treatment responses depend on disease severity, plasma drug concentration and anatomical connectivity within the network.

[1]  G. Iannetti,et al.  BOLD functional MRI in disease and pharmacological studies: room for improvement? , 2007, Magnetic resonance imaging.

[2]  Karl J. Friston,et al.  Comparing Families of Dynamic Causal Models , 2010, PLoS Comput. Biol..

[3]  Michael C. Anderson,et al.  Selection and stopping in voluntary action: A meta-analysis and combined fMRI study , 2014, NeuroImage.

[4]  C. Segebarth,et al.  Identifying Neural Drivers with Functional MRI: An Electrophysiological Validation , 2008, PLoS biology.

[5]  J. Brotchie,et al.  Monoamine Reuptake Inhibitors in Parkinson's Disease , 2015, Parkinson's disease.

[6]  T. Robbins,et al.  Noradrenergic versus dopaminergic modulation of impulsivity, attention and monitoring behaviour in rats performing the stop-signal task , 2013, Psychopharmacology.

[7]  N. Volkow,et al.  Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. , 2007, Nuclear medicine and biology.

[8]  D. Samuel Schwarzkopf,et al.  Effective Connectivity within Human Primary Visual Cortex Predicts Interindividual Diversity in Illusory Perception , 2013, The Journal of Neuroscience.

[9]  Michael J. Frank,et al.  Hold Your Horses: Impulsivity, Deep Brain Stimulation, and Medication in Parkinsonism , 2007, Science.

[10]  A. Nambu,et al.  Functional significance of the cortico–subthalamo–pallidal ‘hyperdirect’ pathway , 2002, Neuroscience Research.

[11]  James B. Rowe,et al.  Reversed Frontotemporal Connectivity During Emotional Face Processing in Remitted Depression , 2012, Biological Psychiatry.

[12]  R. Cools,et al.  Dopaminergic drug effects during reversal learning depend on anatomical connections between the orbitofrontal cortex and the amygdala , 2013, Front. Neurosci..

[13]  Roger A. Barker,et al.  White matter pathology in Parkinson's disease: The effect of imaging protocol differences and relevance to executive function , 2012, NeuroImage.

[14]  Luca Passamonti,et al.  Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease , 2016, Neuropsychopharmacology.

[15]  T. Robbins,et al.  Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease , 2014, Brain : a journal of neurology.

[16]  T. Cummins,et al.  Dopamine transporter genotype predicts behavioural and neural measures of response inhibition , 2012, Molecular Psychiatry.

[17]  Thomas V. Wiecki,et al.  A computational model of inhibitory control in frontal cortex and basal ganglia. , 2011, Psychological review.

[18]  Karl J. Friston,et al.  Nonlinear Dynamic Causal Models for Fmri Nonlinear Dynamic Causal Models for Fmri Nonlinear Dynamic Causal Models for Fmri , 2022 .

[19]  C. Wheeler-Kingshott,et al.  About “axial” and “radial” diffusivities , 2009, Magnetic resonance in medicine.

[20]  M. Manfredi,et al.  Deep brain stimulation of subthalamic nuclei affects arm response inhibition in Parkinson's patients. , 2012, Cerebral cortex.

[21]  David J. Brooks,et al.  Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study , 2014, Brain : a journal of neurology.

[22]  Karl J. Friston,et al.  Bayesian model selection for group studies , 2009, NeuroImage.

[23]  Roger A. Barker,et al.  Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment? , 2010, NeuroImage.

[24]  G. Logan.  On the ability to inhibit thought and action , 1984 .

[25]  Jason B. Mattingley,et al.  Executive “Brake Failure” following Deactivation of Human Frontal Lobe , 2006, Journal of Cognitive Neuroscience.

[26]  Peter S. Jones,et al.  Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures , 2016, Human brain mapping.

[27]  A. Grace,et al.  Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[28]  S. Swinnen,et al.  Aging and Inhibitory Control of Action: Cortico-Subthalamic Connection Strength Predicts Stopping Performance , 2012, The Journal of Neuroscience.

[29]  Roshan Cools,et al.  Anatomical connection strength predicts dopaminergic drug effects on fronto-striatal function , 2013, Psychopharmacology.

[30]  Hartwig R. Siebner,et al.  Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans , 2015, Brain : a journal of neurology.

[31]  C. Baunez,et al.  Is there an inhibitory-response-control system in the rat? Evidence from anatomical and pharmacological studies of behavioral inhibition , 2010, Neuroscience & Biobehavioral Reviews.

[32]  C. Li,et al.  Behavioral/systems/cognitive Functional Connectivity Delineates Distinct Roles of the Inferior Frontal Cortex and Presupplementary Motor Area in Stop Signal Inhibition , 2022 .

[33]  P. Morosan,et al.  Broca's Region: Novel Organizational Principles and Multiple Receptor Mapping , 2010, PLoS biology.

[34]  William D. Marslen-Wilson,et al.  The Cambridge Centre for Ageing and Neuroscience (Cam-CAN) study protocol: a cross-sectional, lifespan, multidisciplinary examination of healthy cognitive ageing , 2014, BMC Neurology.

[35]  Karl J. Friston,et al.  Tractography-based priors for dynamic causal models , 2009, NeuroImage.

[36]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[37]  T. Robbins,et al.  Inhibition and the right inferior frontal cortex: one decade on , 2014, Trends in Cognitive Sciences.

[38]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[39]  J. Rowe.  Frontiers in Systems Neuroscience Systems Neuroscience , 2010 .

[40]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[41]  Roger A. Barker,et al.  Targeting impulsivity in Parkinson’s disease using atomoxetine , 2014, Brain : a journal of neurology.

[42]  B. Yamamoto,et al.  Regulation of Extracellular Dopamine by the Norepinephrine Transporter , 1998, Journal of neurochemistry.

[43]  Karl J. Friston,et al.  Analysing connectivity with Granger causality and dynamic causal modelling , 2013, Current Opinion in Neurobiology.

[44]  Karl J. Friston,et al.  Resting state functional MRI in Parkinson’s disease: the impact of deep brain stimulation on ‘effective’ connectivity , 2014, Brain : a journal of neurology.

[45]  Karl J. Friston,et al.  Free Energy, Precision and Learning: The Role of Cholinergic Neuromodulation , 2013, The Journal of Neuroscience.

[46]  H. Bergman,et al.  Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease , 2010, Nature Reviews Neuroscience.

[47]  Tipu Z. Aziz,et al.  The role of the subthalamic nucleus in response inhibition: Evidence from local field potential recordings in the human subthalamic nucleus , 2012, NeuroImage.

[48]  Hartwig R. Siebner,et al.  The acute brain response to levodopa heralds dyskinesias in Parkinson disease , 2014, Annals of neurology.

[49]  T. Robbins,et al.  Atomoxetine Improved Response Inhibition in Adults with Attention Deficit/Hyperactivity Disorder , 2007, Biological Psychiatry.

[50]  S. Houle,et al.  Stimulation of the subthalamic nucleus and impulsivity: Release your horses , 2009, Annals of neurology.

[51]  Marjan Jahanshahi,et al.  Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson’s disease , 2011, Experimental Brain Research.

[52]  K. Perry,et al.  Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder , 2002, Neuropsychopharmacology.

[53]  M. Rietschel,et al.  Adolescent impulsivity phenotypes characterized by distinct brain networks , 2012, Nature Neuroscience.

[54]  John-Michael Sauer,et al.  Clinical Pharmacokinetics of Atomoxetine , 2005, Clinical pharmacokinetics.

[55]  Roger A. Barker,et al.  Improving Response Inhibition in Parkinson’s Disease with Atomoxetine , 2015, Biological Psychiatry.

[56]  T. Robbins,et al.  The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks , 2008, Psychopharmacology.

[57]  James B. Rowe,et al.  Multiple Modes of Impulsivity in Parkinson's Disease , 2014, PloS one.

[58]  R. Barker,et al.  Parkinson's disease and healthy aging: Independent and interacting effects on action selection , 2010, Human brain mapping.

[59]  T. Robbins,et al.  Atomoxetine Modulates Right Inferior Frontal Activation During Inhibitory Control: A Pharmacological Functional Magnetic Resonance Imaging Study , 2009, Biological Psychiatry.

[60]  Michael J. Brammer,et al.  Shared and Drug-Specific Effects of Atomoxetine and Methylphenidate on Inhibitory Brain Dysfunction in Medication-Naive ADHD Boys , 2012, Cerebral cortex.

[61]  D. Goldstein,et al.  Catechols in post‐mortem brain of patients with Parkinson disease , 2011, European journal of neurology.

[62]  T. Robbins,et al.  Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans , 2003, Nature Neuroscience.

[63]  Gary Aston-Jones,et al.  The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease , 2012, Front. Behav. Neurosci..

[64]  Karl J. Friston,et al.  False discovery rate revisited: FDR and topological inference using Gaussian random fields , 2009, NeuroImage.

[65]  J. Gallacher,et al.  HOLD YOUR HORSES , 1998 .

[66]  M. Filippi,et al.  White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[67]  Raymond J. Dolan,et al.  Profiling neuronal ion channelopathies with non-invasive brain imaging and dynamic causal models: Case studies of single gene mutations , 2016, NeuroImage.

[68]  Daniel Rueckert,et al.  Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data , 2006, NeuroImage.

[69]  Melissa Gerstenhaber,et al.  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[70]  Stephen M. Smith,et al.  Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference , 2009, NeuroImage.

[71]  G. Fink,et al.  Dopaminergic modulation of motor network dynamics in Parkinson’s disease , 2015, Brain : a journal of neurology.

[72]  Pierre-Louis Bazin,et al.  Cortico-subthalamic white matter tract strength predicts interindividual efficacy in stopping a motor response , 2012, NeuroImage.

[73]  Roger A. Barker,et al.  Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions , 2012, Cerebral cortex.

[74]  Gereon R Fink,et al.  Noradrenergic enhancement improves motor network connectivity in stroke patients , 2011, Annals of neurology.

[75]  T. Robbins,et al.  Prefrontal and Monoaminergic Contributions to Stop-Signal Task Performance in Rats , 2011, The Journal of Neuroscience.

[76]  Karl J. Friston,et al.  Ten simple rules for dynamic causal modeling , 2010, NeuroImage.

[77]  Michael C. Anderson,et al.  The Prefrontal Cortex Achieves Inhibitory Control by Facilitating Subcortical Motor Pathway Connectivity , 2015, The Journal of Neuroscience.

[78]  Marjan Jahanshahi,et al.  Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson’s disease , 2011, Experimental Brain Research.

[79]  Karl J. Friston,et al.  Dynamic causal modelling , 2003, NeuroImage.

[80]  R. Mahajan,et al.  Effects of norepinephrine and glyceryl trinitrate on cerebral haemodynamics: transcranial Doppler study in healthy volunteers. , 2008, British journal of anaesthesia.

[81]  William D. Penny,et al.  Age-related changes in causal interactions between cortical motor regions during hand grip , 2012, NeuroImage.

[82]  Erwan Bezard,et al.  Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders , 2009, The Lancet Neurology.

[83]  Karl J. Friston,et al.  Bayesian model selection for group studies — Revisited , 2014, NeuroImage.

[84]  Robert Hester,et al.  Dopamine D2 Receptor Modulation of Human Response Inhibition and Error Awareness , 2013, Journal of Cognitive Neuroscience.

[85]  T. Robbins,et al.  Characterizing mild cognitive impairment in incident Parkinson disease , 2014, Neurology.